OSE Immunotherapeutics SA (EPA:OSE)

OSE Immunotherapeutics Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	69.88	2.23	18.3	26.31	10.42
Other Revenue	13.56	-	-	-	0
Revenue	83.44	2.23	18.3	26.31	10.42
Revenue Growth (YoY)	3646.52%	-87.83%	-30.43%	152.48%	-59.85%
Gross Profit	83.44	2.23	18.3	26.31	10.42
Selling, General & Admin	6.26	5.96	6.59	8.5	4.7
Research & Development	30.45	17.09	26.82	30.49	22.31
Other Operating Expenses	0.27	0.13	0.24	0.16	0.12
Operating Expenses	39.7	25.21	36.78	42.93	29.41
Operating Income	43.74	-22.99	-18.48	-16.63	-18.99
Interest Expense	-3.17	-2.2	-1.37	-0.84	-0.27
Interest & Investment Income	1.47	0.34	0.02	0.01	0.01
Currency Exchange Gain (Loss)	-0.02	-0.04	-0	0.04	0
Other Non Operating Income (Expenses)	-2.41	1.66	1.82	0.2	-0
EBT Excluding Unusual Items	39.6	-23.23	-18.02	-17.22	-19.25
Gain (Loss) on Sale of Investments	0.23	0	-	0	-
Pretax Income	39.83	-23.22	-18.02	-17.21	-19.25
Income Tax Expense	2.39	-0.22	-0.26	-0.36	-2.69
Net Income	37.45	-23	-17.76	-16.85	-16.56
Net Income to Common	37.45	-23	-17.76	-16.85	-16.56
Shares Outstanding (Basic)	22	20	19	18	16
Shares Outstanding (Diluted)	26	20	19	18	16
Shares Change (YoY)	31.11%	5.58%	2.05%	16.71%	4.46%
EPS (Basic)	1.72	-1.18	-0.96	-0.93	-1.06
EPS (Diluted)	1.46	-1.18	-0.96	-0.93	-1.06
Free Cash Flow	48.36	-19.78	-18.53	-10.39	-19.76
Free Cash Flow Per Share	1.89	-1.01	-1.00	-0.57	-1.27
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	52.42%	-1032.15%	-100.96%	-63.20%	-182.25%
Profit Margin	44.88%	-1032.91%	-97.04%	-64.05%	-158.89%
Free Cash Flow Margin	57.97%	-888.19%	-101.22%	-39.50%	-189.65%
EBITDA	43.95	-20.31	-15.68	-14.66	-18.72
EBITDA Margin	52.67%	-	-85.69%	-55.71%	-179.63%
D&A For EBITDA	0.21	2.68	2.8	1.97	0.27
EBIT	43.74	-22.99	-18.48	-16.63	-18.99
EBIT Margin	52.42%	-	-100.96%	-63.20%	-182.25%
Effective Tax Rate	5.99%	-	-	-	-
Revenue as Reported	-	-	18.3	26.31	10.43

Updated Dec 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.